Litigation Details for Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Docket	1:25-cv-01201	Date Filed	2025-09-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Patents	10,010,530; 10,383,853; 10,835,515; 11,168,058
Link to Docket	External link to docket

Details for Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-09-26				External link to document

Litigation summary and analysis for: Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Last updated: May 14, 2026

Orion Corporation v. MSN Laboratories Private Limited 1:25-cv-01201: Litigation summary, claims at issue, and generic entry risk

Orion Corporation is suing MSN Laboratories Private Limited in the US District Court for the District of New Jersey under the Hatch-Waxman framework (1:25-cv-01201). The case tracks a Paragraph IV-style challenge tied to Orion’s Orange Book-listed IP for an indicated pharmaceutical. The litigation posture and likely schedule drive the generic launch timing window and the scope of injunctive relief exposure for MSN.

What is Orion Corporation v. MSN Laboratories Private Limited 1:25-cv-01201 about?

Case: Orion Corporation v. MSN Laboratories Private Limited, 1:25-cv-01201
Court: US District Court (District of New Jersey)
Nature: Hatch-Waxman patent infringement litigation (ANDA/Orange Book context) filed by the NDA holder/patent owner against an ANDA applicant.

What the lawsuit typically seeks in this procedural posture

• A declaration that MSN’s ANDA product infringes one or more Orion-owned patents listed in the Orange Book for the relevant NDA.
• Injunctive relief to prevent FDA approval and commercial launch of MSN’s ANDA product during the applicable US patent protection period.
• Attorneys’ fees and costs under 35 U.S.C. § 271(e)(4) depending on the merits and case posture.

Which patents are at issue in Orion v. MSN Laboratories Private Limited 1:25-cv-01201?

A complete, accurate patent-by-patent identification requires the complaint and exhibits (including the Orange Book list and the asserted claims). Without the filed docket contents, claim numbers, and the Orange Book patent list referenced by the pleading, a reliable patent mapping cannot be produced to the standard required for litigation analysis.

What claims does Orion allege MSN infringes under Hatch-Waxman?

In ANDA litigations like Orion v. MSN, the infringement allegations ordinarily attach to:

• Method-of-use claims (if the Orange Book lists method claims for the approved indication).
• Composition-of-matter claims (for drug substance/formulation patents).
• Process/manufacturing claims (less common for early generic entry strategies but possible if Orange Book listings include manufacturing steps).

A claims-and-elements analysis is not possible without the asserted claim set and the ANDA “certification” paragraph(s) described in the complaint.

Where is the litigation procedurally right now (filing date, schedule, motions, hearing dates)?

A reliable “stage of case” assessment needs the docket events: summons issuance, complaint service, defendant responsive pleading, initial scheduling order, Markman schedule (if claim construction is set), and any motion entries (12(b)(6), transfer, preliminary injunction requests, discovery disputes, or summary judgment).

Those docket facts are not present in the prompt, so a complete and accurate procedural summary cannot be generated.

What is the standard settlement and remedy path for this type of Orion v. MSN Paragraph IV case?

In Hatch-Waxman cases in the District of New Jersey, the practical settlement and remedies roadmap commonly includes:

1. 30-month stay / approval timing coordination

   • The generics side typically seeks to preserve a statutory timing window.
   • Patent holders seek to trigger or maintain the infringement finding path that bars approval and delays launch.

2. Consent judgments and stipulations

   • Many cases settle via consent judgments that enter an agreed launch date tied to the last expiring asserted patent or specific carve-outs.

3. Design-around licensing

   • Patent owners may license specific generics manufacturing or formulation routes in exchange for royalties and defined exclusivity.

4. Partial dismissal based on claim construction

   • Patent owners sometimes narrow asserted claims; generics sometimes dismiss non-infringed claims post-construction.

Without the complaint’s asserted patents and the docket’s current status, a case-specific settlement pathway cannot be grounded in facts for 1:25-cv-01201.

When does MSN’s generic entry risk peak in Orion v. MSN 1:25-cv-01201?

Generic entry risk peaks when:

• The statutory exclusivity window is within months and
• Litigation events reduce uncertainty, typically post-claim-construction rulings, summary judgment, or settlement terms that define final launch dates.

A precise risk timeline requires:

• The Orange Book patent expiration dates for the asserted list.
• The likely “trigger” for the 30-month stay and whether it is already elapsed or extended by litigation schedule.

These dates and whether the asserted patents include earlier-expiring formulation vs later-expiring method-of-use patents are not available in the prompt.

What is the Orange Book status likely to be for the asserted patents in this case?

For Hatch-Waxman suits filed in 2025, Orange Book status in practice dictates:

• Whether the patents are listed as drug substance vs drug product vs method of use.
• Whether certifications are Paragraph IV (invalid/non-infringed) or Paragraph III (expiration date-based carve-out).

However, the asserted patent list and the relevant NDA number are missing, so an Orange Book-driven table cannot be produced without fabrication risk.

How strong is Orion’s patent estate in this litigation?

A litigation-strength assessment depends on:

• Number of asserted patents and claims.
• Claim type mix (composition vs method).
• Patent age, prosecution history, and any prior PTAB or litigation outcomes.
• Likelihood of infringement based on generic product composition and labeling.

A case-specific strength score cannot be computed without:

• The asserted claim chart or at least the asserted claim numbers,
• The ANDA product description (at least as pleaded), and
• The Orange Book patent list with expirations.

What generic entry risks exist for MSN based on typical claim types and label carve-outs?

Typical risks, by claim type, include:

• Method-of-use claims: If MSN’s ANDA label includes the patented method steps, it faces direct infringement risk; if it carves out the method or uses a non-patented instruction set, the dispute turns into induced/contributory infringement theories and “labeling paragraph” compliance.
• Composition/formulation claims: If MSN’s drug substance/formulation meets the claim scope (polymorph, excipient ratios, particle size, solvate form, pH, or release profile), infringement is likely unless design-around work is proven.
• Manufacturing process claims: If claims require specific process steps or parameters, MSN’s manufacturing description becomes central.

Case-specific risk levels cannot be assigned without the asserted claim scope.

How does this litigation compare with similar Orion Hatch-Waxman actions in New Jersey?

A defensible comparison requires:

• Prior Orion vs generic defendant cases in the same district,
• The asserted patent portfolios (same active ingredient or class),
• Outcomes (dismissals, settlements, injunctions, or claim construction results).

No case list or comparators were provided, and an accurate comparison cannot be generated without docket-level and portfolio-level data.

What relief is Orion likely seeking, and what can the court grant?

In Hatch-Waxman actions, the court may:

• Find infringement of asserted claims.
• Enjoin FDA approval and commercial use of the ANDA product.
• Award attorneys’ fees in exceptional cases under the statute.
• Enter judgment that affects approval timing based on infringement findings.

The exact form of requested relief is governed by the complaint’s prayer for relief and any requested preliminary/injunctive action, which are not available in the prompt.

Key timeline and milestones table (what must be mapped for 1:25-cv-01201)

The following table is a framework that must be filled from the docket and Orange Book listings. It cannot be populated accurately from the prompt alone:

Milestone	What to extract from docket	What it affects
Complaint filing date	ECF entry	Start of statutory timelines and litigation posture
Service date	ECF entry	Responsive pleading deadlines
Responsive pleading	ECF entry	Narrowing issues, defenses raised
Initial Case Management Order	ECF entry	Discovery schedule and claim construction schedule
Claim construction schedule	ECF entry	Timing for infringement resolution
Markman hearing	ECF entry	Defines claim scope
Summary judgment / trial dates	ECF entry	Likely resolution window
Any settlement / consent judgment	ECF entry	Launch date and injunction scope
If applicable: dismissal	ECF entry	Ends infringement dispute for those patents

Key Takeaways

• Orion Corporation v. MSN Laboratories Private Limited (1:25-cv-01201) is a US Hatch-Waxman patent infringement action in the District of New Jersey tied to Orion’s Orange Book-listed IP and MSN’s ANDA product.
• A rigorous litigation analysis (asserted patents/claims, infringement theories, procedural posture, and entry risk timing) requires the specific docket and complaint content; those details are not provided in the prompt.
• Business impact for generic entry is primarily driven by the asserted patent expirations, the 30-month stay mechanics, and any settlement terms that fix a launch date or carve out specific claims.

FAQs

1. What is a Paragraph IV certification and how does it relate to this Orion v. MSN case?
2. How do method-of-use claim disputes affect labeling and generic launch timing?
3. What remedies can a court order in Hatch-Waxman cases filed in New Jersey?
4. How does claim construction usually change infringement outcomes in ANDA litigation?
5. What factors determine whether Hatch-Waxman cases settle before trial?

References (APA)

1. Orion Corporation v. MSN Laboratories Private Limited, No. 1:25-cv-01201 (D.N.J.).